Psoriasis Treatment in Thiruvananthapuram – Advanced Dermatology Care | DermaVue

Name: Psoriasis Treatment in Thiruvananthapuram
Brand: DermaVue
SKU: TVM-PSO-001
Price: 300 INR
Availability: InStock
Rating: 4.7 (1309 reviews)

DermaVue Medical Team

DERMAVUE THIRUVANANTHAPURAM (TRIVANDRUM) — PSORIASIS SPECIALISTS

Psoriasis Treatment in Thiruvananthapuram — MD DVL Dermatologists, Biologics & PASI-Guided Care

4.7 (1309+ Reviews) Board-Certified MD DVL IL-17 / IL-23 / TNF Biologics PASI · BSA · DLQI Assessment PEST Screening for PsA

Psoriasis is a chronic, immune-mediated, T-cell driven inflammatory disease affecting roughly 0.44–2.8% of the Indian population — over 8 million people living with moderate-to-severe disease (IJDVL, IADVL). At DermaVue Thiruvananthapuram, board-certified MD DVL dermatologists assess every patient with standardised PASI, Body Surface Area (BSA) and Dermatology Life Quality Index (DLQI) scoring, screen for psoriatic arthritis using validated PEST and CASPAR criteria, and address the metabolic, cardiovascular and hepatic comorbidities now recognised by the AAD and National Psoriasis Foundation as integral to psoriasis care. Our treatment ladder spans topical calcipotriol, tazarotene, tacrolimus and calibrated topical corticosteroids; narrowband UVB (NB-UVB) phototherapy; conventional systemics (methotrexate, cyclosporine, acitretin, apremilast); the oral TYK2 inhibitor deucravacitinib; and IL-17 (secukinumab, ixekizumab), IL-23 (guselkumab, risankizumab), IL-12/23 and TNF-alpha (adalimumab) biologics — each preceded by mandatory tuberculosis screening per Indian consensus guidelines.

WhatsApp TVM

4.7★ — 1309+ Google Reviews Board-Certified MD DVL IADVL Registered US-FDA Approved Physician-Performed

Pattom 12 min Kowdiar 14 min Vellayambalam 16 min Nalanchira 10 min Kesavadasapuram 16 min Ulloor 15 min Technopark 18 min Kazhakkoottam 22 min Sreekaryam 20 min Medical College 8 min Peroorkada 18 min Mannanthala 25 min Kovalam 30 min Balaramapuram 25 min Pappanamcode 22 min Venganoor 25 min Kalliyoor 18 min Menamkulam 20 min Neyyattinkara 35 min Nedumangad 38 min Attingal 40 min Varkala 45 min Vakkom 35 min Kattakada 30 min Nagercoil 65 min

PSORIASIS IN INDIA — THE DATA

Understanding Psoriasis in Kerala

Evidence-based statistics that inform our climate-adapted treatment protocols for Thiruvananthapuram patients.

0.44–2.8%

Psoriasis Prevalence in India

Over 8 million Indians live with moderate-to-severe psoriasis, making specialist dermatological care essential for disease management.

Source: IADVL Guidelines

41.2%

Metabolic Syndrome in Psoriatic Patients

South Indian tertiary centres report metabolic syndrome in 41.2% of psoriasis patients — obesity, diabetes, hypertension requiring integrated care.

Source: South Indian tertiary centre data

92%

Indian Dermatologists Prefer Methotrexate

IADVL survey shows 92% of Indian dermatologists use methotrexate as first-line systemic for moderate-to-severe psoriasis, reflecting cost-effectiveness and familiarity.

Source: IADVL Consensus Statement

TB Screen

Mandatory Before Biologics

India’s TB burden makes tuberculosis screening (Mantoux/IGRA) mandatory before initiating any biologic therapy for psoriasis — a critical safety step.

Source: Indian Dermatology Guidelines

Up to 30%

Develop Psoriatic Arthritis (PsA)

Up to 30% of psoriasis patients develop psoriatic arthritis — often 7–10 years after skin onset. PEST and CASPAR screening at every visit enables early diagnosis and disease-modifying therapy before irreversible joint damage.

Source: AAD-NPF Joint Guidelines, 2020

1309+

Patient Reviews at 4.7★

DermaVue Thiruvananthapuram is among the highest-rated dermatology clinics in the capital city, with physician-performed procedures and evidence-based protocols.

Source: Google Reviews

UNDERSTANDING YOUR CONDITION

Types of Psoriasis We Treat

Psoriasis is a chronic autoimmune condition causing rapid skin cell turnover. Our dermatologists diagnose and treat all clinical subtypes with personalised protocols. According to the National Psoriasis Foundation, accurate subtype identification is critical for treatment selection.

What is psoriasis? Psoriasis is a chronic, immune-mediated inflammatory disease driven by dysregulation of the IL-23/Th17 axis, in which activated T-cells accelerate keratinocyte turnover and produce well-demarcated erythematous plaques covered by silvery scale. It is not contagious. Indian prevalence is 0.44–2.8% (over 8 million people with moderate-to-severe disease per IJDVL/IADVL data), and up to 30% of patients develop psoriatic arthritis. Severity is measured objectively using PASI, BSA and DLQI; moderate-to-severe disease is defined per AAD and NICE as any score above 10. With guideline-concordant care — topicals, NB-UVB phototherapy, conventional systemics (methotrexate, cyclosporine, acitretin, apremilast), the oral TYK2 inhibitor deucravacitinib, and IL-17/IL-23/TNF biologics — 75–90% of patients achieve PASI 75 or better (AAD-NPF joint guidelines, 2020–2023). DermaVue Thiruvananthapuram (Trivandrum) delivers the full ladder of care under board-certified MD DVL dermatologists, with mandatory tuberculosis screening before biologics and routine evaluation of cardiovascular, metabolic and hepatic comorbidities.

Plaque Psoriasis (Psoriasis Vulgaris)

The most common phenotype (80–90% of cases). Sharply demarcated erythematous plaques with adherent silvery scale, classically on extensor surfaces — elbows, knees, sacrum and scalp. New plaques can arise at sites of skin trauma (the Koebner phenomenon). Severity is graded objectively using PASI, BSA and DLQI to guide topical, phototherapy, systemic or biologic choices.

Guttate Psoriasis

Crops of small (2–10 mm) drop-shaped papules, typically erupting 2–3 weeks after streptococcal pharyngitis or tonsillitis in genetically susceptible individuals. Most common in children and young adults. Throat swab and ASO titre are indicated; NB-UVB phototherapy gives excellent clearance in most cases.

Inverse (Flexural) Psoriasis

Smooth, shiny, sharply marginated erythema in intertriginous areas — inguinal, axillary, inframammary and gluteal folds. Scale is usually absent due to moisture. Requires gentle, non-atrophogenic therapy (low-potency steroids, tacrolimus, calcipotriol) and concurrent treatment of Candida or dermatophyte superinfection when present.

Scalp Psoriasis

Affects around 50% of psoriasis patients, with thick, well-demarcated plaques extending beyond the hairline. Treatment combines medicated shampoos (ketoconazole, coal tar, salicylic acid), clobetasol foam or solution, calcipotriol scalp application and targeted intralesional triamcinolone for refractory plaques — preserving hair integrity throughout the course.

Nail Psoriasis

Pitting, oil-drop discolouration, onycholysis, subungual hyperkeratosis and splinter haemorrhages, present in roughly 50% of psoriasis patients. Nail involvement correlates with higher risk of psoriatic arthritis. IL-17 and IL-23 biologics give the most robust nail clearance in 6–12 months; intralesional matrix steroid is used for focal disease.

Pustular & Erythrodermic Variants

Pustular psoriasis ranges from localised palmoplantar pustulosis to acute generalised pustular psoriasis (von Zumbusch type) — a dermatological emergency with fever and systemic inflammation. Erythrodermic psoriasis (>90% BSA erythema) risks dysthermia and high-output cardiac failure. Both require urgent hospital-level care with acitretin, cyclosporine, infliximab or IL-36 receptor antagonist therapy.

EVIDENCE-BASED TREATMENT LADDER

Psoriasis Treatment Protocols — AAD-NPF & IADVL Concordant

DermaVue Thiruvananthapuram follows the joint AAD-NPF (American Academy of Dermatology — National Psoriasis Foundation) guidelines and IADVL consensus, with step-up or step-down decisions guided by PASI, BSA, DLQI, psoriatic arthritis status, comorbidities and patient preference.

1

Topical Therapy

Topical corticosteroids (potency matched to site), calcipotriol (vitamin D3 analogue), calcipotriol-betamethasone fixed-dose combinations, tazarotene, tacrolimus and pimecrolimus for flexural and facial sites, and coal tar for scalp. First-line for mild disease (PASI < 10, BSA < 10%, DLQI < 10).

2

Narrowband UVB Phototherapy

NB-UVB (311–313 nm) is the phototherapy of choice for moderate plaque and guttate psoriasis: 2–3 sessions weekly over 20–30 sessions, with PASI 75 achieved in roughly 62–75% of patients per AAD pooled data. Safe in pregnancy and in children when indicated.

3

Conventional & Oral Targeted Systemics

Methotrexate (IADVL first-line, 92% dermatologist preference), cyclosporine for rapid disease control, acitretin for pustular and palmoplantar disease, apremilast (oral PDE4 inhibitor) for moderate disease with metabolic considerations, and deucravacitinib (oral TYK2 inhibitor) as a newer alternative with favourable safety profile. Requires baseline LFT, RFT, CBC, hepatitis and pregnancy assessment.

4

Biologic Therapy

TNF-alpha inhibitor adalimumab; IL-17A inhibitors secukinumab and ixekizumab; IL-23p19 inhibitors guselkumab and risankizumab; and IL-12/23 inhibitor ustekinumab. IL-23 inhibitors report PASI 90 in 70–80% and PASI 100 in 40–55% of patients in head-to-head trials. Mandatory pre-treatment screening: Mantoux/IGRA for latent TB, HBV/HCV serology, HIV, LFT and chest X-ray, per Indian consensus.

Topical & Phototherapy Details

Potency-matched topical corticosteroids for acute flare control with planned step-down
Calcipotriol and calcipotriol-betamethasone foam/gel for maintenance
Tazarotene (retinoid) for thick chronic plaques and nail disease
Tacrolimus and pimecrolimus ointment for face, flexures and genitals
Coal tar and salicylic acid preparations for scalp and hyperkeratotic sites
NB-UVB 311 nm phototherapy — 2–3 sessions weekly, 20–30 session course

Systemic, Targeted & Biologic Details

Methotrexate: weekly oral or subcutaneous dosing with folic acid; quarterly LFT and CBC monitoring
Cyclosporine: short-course (up to 12 weeks) for rapid control of severe flares and erythroderma
Acitretin: preferred for pustular, palmoplantar and HIV-associated psoriasis
Apremilast (PDE4) — oral, no routine lab monitoring required
Deucravacitinib (TYK2) — newer oral targeted agent with improved efficacy over apremilast
IL-17 inhibitors (secukinumab, ixekizumab) — rapid onset, strong scalp and nail clearance
IL-23 inhibitors (guselkumab, risankizumab) — quarterly dosing, durable PASI 90/100 responses
Adalimumab (TNF-alpha) — preferred when concurrent psoriatic arthritis dictates systemic therapy
Mandatory Mantoux or IGRA tuberculosis screening before all biologics (Indian TB burden)

These targeted therapies interrupt specific steps of the IL-23/Th17 inflammatory axis. Protocols at DermaVue Thiruvananthapuram align with the AAD-NPF joint psoriasis guidelines, NICE CG153 (Psoriasis: assessment and management) and IJDVL / IADVL Indian consensus statements.

PSORIASIS + METABOLIC HEALTH

41.2%

of Psoriatic Patients Have Metabolic Syndrome

South Indian tertiary centre data reveals 41.2% of psoriasis patients have metabolic syndrome — including insulin resistance, abdominal obesity, dyslipidemia, and hypertension. Untreated, this dramatically increases cardiovascular risk. Psoriasis is no longer a “skin-only” disease.

At DermaVue, we screen every moderate-to-severe psoriasis patient for metabolic comorbidities and offer integrated management through our SuperHuman Medical Weight Loss Programme — combining GLP-1 receptor agonist therapy with dermatological care.

SuperHuman Weight Loss Programme

GLP-1 receptor agonist therapy under physician supervision
Weight loss reduces psoriasis severity by 50–75% in obese patients
Metabolic panel monitoring alongside psoriasis treatment
Cardiovascular risk reduction with inflammatory markers tracking

COMPLEMENTARY APPROACHES

Ayurveda & Psoriasis: What the Evidence Shows

Many psoriasis patients ask about integrating complementary traditional treatments alongside dermatology care. Here is what the published evidence indicates.

Evidence Review: Ayurvedic Interventions for Psoriasis

A systematic review identified 17 published studies on Ayurvedic interventions for psoriasis. All 17 were case reports or case series — none were randomised controlled trials (RCTs). Without RCT-level evidence, it is not possible to confirm efficacy beyond anecdotal observation.

DermaVue’s position: Ayurveda may complement evidence-based dermatological treatment; current evidence is insufficient to replace conventional therapy. Patients wishing to explore Ayurvedic approaches should inform their dermatologist to avoid harmful interactions (e.g., herbal hepatotoxins with methotrexate).

Evidence Level: Case Reports Only — Not RCTs

SEASONAL TRIGGERS & KOEBNER PHENOMENON

Environmental Triggers and Seasonal Flares

Psoriasis is trigger-sensitive. Streptococcal infection, skin trauma (Koebner phenomenon), certain drugs (beta-blockers, lithium, antimalarials, systemic steroid withdrawal), alcohol and smoking are all well-documented precipitants. In tropical climates such as Thiruvananthapuram’s, the June–November high-humidity period also increases strep pharyngitis incidence and exacerbates flexural disease — requiring protocol adjustments that are built into every DermaVue management plan.

Guttate Psoriasis & Humid-Season Infections

Streptococcal throat infections rise during high-humidity months
Guttate psoriasis erupts 2–3 weeks after strep infection
Prompt antibiotic treatment for sore throats reduces flare risk
Preventive gargling protocols during high-humidity months

Inverse Psoriasis & Humidity

High humidity worsens inverse psoriasis in skin folds
Secondary fungal/bacterial infections common in moist folds
Antifungal co-treatment prevents Candida superinfection
Clothing guidance: loose, breathable fabrics; avoid synthetics

WATCH & LEARN

Psoriasis Education Videos

Our dermatologists explain psoriasis causes, treatments, and medication safety in Malayalam for Kerala patients.

What is Psoriasis Malayalam

Misuse of Topical Steroid Creams

PSORIASIS SEVERITY ESTIMATOR

Check Your Psoriasis Severity

Rate your symptoms on the sliders below and select your affected body area to get an approximate PASI range and treatment pathway recommendation.

Redness (Erythema): 0/10

0 = None · 10 = Very severe redness

Thickness (Induration): 0/10

0 = None · 10 = Very thick plaques

Scaliness (Desquamation): 0/10

0 = None · 10 = Very heavy scaling

Primary Body Area Affected

Itching Severity: 0/10

0 = No itching · 10 = Unbearable itching

Impact on Daily Life

COMPARE YOUR OPTIONS

DermaVue vs. Average Clinic for Psoriasis

Feature	DermaVue TVM	Average Clinic
Doctor Qualification	✓ MD DVL Board-Certified Dermatologists	✕ Non-specialist practitioner
Biologics Therapy	✓ TNF, IL-17, IL-23 Inhibitors	✕ Basic Topicals Only
Severity Assessment	✓ PASI + BSA + DLQI scoring + photographic baseline	✕ Visual estimate only
TB Screening Before Biologics	✓ Mantoux + IGRA Protocol	✕ Often Skipped
Psoriatic Arthritis Screening	✓ PEST questionnaire + CASPAR criteria, every visit	✕ Not routinely assessed
Oral Targeted Therapy	✓ Apremilast (PDE4) + Deucravacitinib (TYK2)	✕ Not offered
Metabolic Syndrome Screening	✓ Full Panel + SuperHuman Programme	✕ Skin-Only Focus
Climate-Adapted Protocols	✓ Humid + Dry Season Plans	✕ Generic Approach
Reviews	✓ 4.7★ — 1309+ Google Reviews	✕ Unrated / Few Reviews

FREQUENTLY ASKED QUESTIONS

Psoriasis Treatment FAQs — Thiruvananthapuram

Is psoriasis contagious, and is it an autoimmune condition?

Psoriasis is not contagious under any circumstances — it cannot spread through touch, shared towels, swimming pools or physical intimacy. It is an immune-mediated inflammatory disease driven by overactive T-cells and the IL-23/Th17 axis, resulting in accelerated keratinocyte turnover. Because the underlying mechanism is systemic immune dysregulation, modern treatment targets these specific inflammatory pathways rather than just the visible skin lesions.

How do you assess severity at DermaVue Thiruvananthapuram — is it just a visual estimate?

Every patient receives standardised assessment using three validated tools: PASI (Psoriasis Area and Severity Index), BSA (Body Surface Area), and DLQI (Dermatology Life Quality Index). Per AAD and NICE guidance, moderate-to-severe disease is defined as PASI greater than 10, BSA above 10%, or DLQI above 10. We also photograph representative lesions at baseline and each follow-up to objectively track response to therapy, and screen for psoriatic arthritis using the validated PEST questionnaire at every visit.

Does my psoriasis mean I am at risk of psoriatic arthritis, and how is it screened?

Up to 30% of psoriasis patients develop psoriatic arthritis (PsA), most commonly 7 to 10 years after skin onset. At DermaVue Thiruvananthapuram we screen every patient using the PEST (Psoriasis Epidemiology Screening Tool) questionnaire and apply CASPAR criteria when PsA is suspected — looking for dactylitis, enthesitis, nail pitting, and inflammatory back pain. Early detection matters because untreated PsA can cause irreversible joint damage within 24 months; patients with positive screening are co-managed with rheumatology.

Which systemic and biologic options are available, and how do you choose between them?

We offer the full evidence-based ladder: methotrexate (first-line systemic per IADVL, preferred by 92% of Indian dermatologists), cyclosporine for rapid control, acitretin for pustular and palmoplantar variants, the oral PDE4 inhibitor apremilast, and the newer oral TYK2 inhibitor deucravacitinib. Biologic options span TNF-alpha (adalimumab), IL-17 (secukinumab, ixekizumab), IL-23 (guselkumab, risankizumab) and IL-12/23 inhibitors. Selection is individualised based on PASI, PsA involvement, comorbidities (NAFLD, metabolic syndrome, latent TB), pregnancy plans and patient preference, following AAD-NPF joint guidelines. Mandatory TB screening via Mantoux or IGRA precedes every biologic given India's tuberculosis burden.

How is scalp, nail and genital psoriasis treated differently from plaque psoriasis?

These special sites require subtype-specific protocols. Scalp psoriasis is treated with medicated shampoos (ketoconazole, salicylic acid, coal tar), topical clobetasol foam/solution, calcipotriol scalp solution, and targeted intralesional triamcinolone for resistant plaques. Nail psoriasis — affecting around 50% of patients — responds to topical tazarotene or calcipotriol under occlusion, intralesional steroid to the nail matrix, and systemic therapy (biologics give the strongest nail clearance). Genital and inverse psoriasis requires gentle, non-atrophogenic agents: low-potency corticosteroids, tacrolimus ointment, and calcipotriol; we avoid potent steroids and tar in flexural sites.

Can Ayurveda cure my psoriasis? What does the published evidence actually show?

A published systematic review of Ayurvedic interventions for psoriasis identified 17 studies — all were case reports or case series, and none were randomised controlled trials. Without RCT-level evidence, efficacy claims beyond anecdote cannot be substantiated. DermaVue's position is that Ayurveda may be explored as a complement to evidence-based dermatological care, but current evidence is insufficient to replace conventional therapy. Patients using Ayurvedic preparations should always inform their dermatologist, because some herbal formulations carry hepatotoxicity risk and can interact dangerously with methotrexate, cyclosporine and acitretin.

Is psoriasis hereditary, and can I pass it to my children?

Genetic predisposition is well established — if one parent has psoriasis, children have roughly a 10 to 25% chance of developing it; if both parents are affected, the risk rises to about 50%. However, environment and triggers determine whether genes are expressed: streptococcal infection (guttate), beta-blockers, lithium, antimalarials, systemic corticosteroid withdrawal, alcohol, smoking and physical trauma (Koebner phenomenon) are all well-documented triggers. Genetic predisposition alone does not guarantee disease, and there is currently no screening test that predicts onset.

I am planning pregnancy — which psoriasis treatments are safe?

Methotrexate and acitretin are strictly contraindicated in pregnancy (methotrexate must be stopped at least 3 months before conception in both men and women; acitretin requires 3 years off therapy in women due to prolonged teratogenicity). Topical emollients, moderate-potency corticosteroids and narrowband UVB phototherapy are generally considered safe in pregnancy. Among biologics, certolizumab pegol is the only agent with minimal placental transfer and is the preferred option for pregnant patients requiring systemic therapy. We coordinate with obstetrics for pre-conception counselling and trimester-specific planning.

Does psoriasis increase my risk of heart disease, diabetes and fatty liver?

Yes — and this is now considered integral to psoriasis care, not a separate issue. South Indian tertiary-centre data show 41.2% of psoriasis patients meet criteria for metabolic syndrome (central obesity, insulin resistance, dyslipidemia, hypertension). Moderate-to-severe psoriasis is independently associated with higher rates of type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and major adverse cardiovascular events, per the AAD-NPF joint guidelines on comorbidity management. At DermaVue Thiruvananthapuram we screen every moderate-to-severe patient with fasting glucose, HbA1c, lipid panel, liver function tests and blood pressure, and offer integrated care through our SuperHuman medical weight-loss programme when indicated.

What does a psoriasis consultation at DermaVue Thiruvananthapuram include, and what does it cost?

The consultation fee at DermaVue Thiruvananthapuram is Rs 300 and covers a full evaluation by a board-certified MD DVL dermatologist: detailed history including triggers and family history, full-skin examination, PASI/BSA/DLQI scoring, PEST screening for psoriatic arthritis, scalp/nail/genital site assessment, photographic baseline, and a written personalised treatment plan with clear step-up and step-down criteria. Baseline investigations (LFT, RFT, lipid panel, HbA1c, TB screening when biologics are planned) are billed separately at published rates. EMI options and patient assistance programmes are available for biologics and advanced systemics.

DermaVue Thiruvananthapuram (Trivandrum) is a physician-owned dermatology clinic delivering specialist psoriasis care under board-certified MD DVL dermatologists at TC 42, Poojappura Main Road, Chengalloor — serving patients across Pattom, Kowdiar, Vellayambalam, Technopark, Kazhakkoottam, Sreekaryam, Peroorkada, Neyyattinkara, Attingal, Varkala and adjoining districts including Kanyakumari. Every patient is evaluated with standardised PASI, BSA and DLQI scoring, screened for psoriatic arthritis using the PEST questionnaire and CASPAR criteria, and assessed for metabolic syndrome, non-alcoholic fatty liver disease and cardiovascular risk — reflecting the AAD-NPF position that psoriasis is a systemic inflammatory disease rather than a skin-only condition.

Treatment protocols at DermaVue Thiruvananthapuram align with international guidelines: the AAD-NPF joint psoriasis guidelines (2020–2023), NICE CG153, and the IADVL / IJDVL Indian consensus statements. The full ladder of care is available — topical calcipotriol, tazarotene, tacrolimus and potency-matched corticosteroids; narrowband UVB phototherapy; conventional systemics (methotrexate preferred by 92% of Indian dermatologists per IADVL, cyclosporine, acitretin); oral targeted agents apremilast and deucravacitinib; and biologics spanning TNF-alpha (adalimumab), IL-17 (secukinumab, ixekizumab), IL-23 (guselkumab, risankizumab) and IL-12/23 inhibitors. All biologic therapy is preceded by mandatory Mantoux or IGRA screening for latent tuberculosis given India\'s TB burden.

With a 4.7-star rating from 1309+ Google reviews, DermaVue is among the highest-rated dermatology clinics in the Kerala capital for psoriasis care, integrating pregnancy-planning counselling, psoriatic arthritis co-management with rheumatology, and metabolic comorbidity management through its SuperHuman medical weight-loss programme. References: American Academy of Dermatology — Psoriasis Guidelines, National Psoriasis Foundation, NICE CG153, Indian Journal of Dermatology, Venereology and Leprology, PubMed / NIH.

Begin Your Psoriasis Treatment Journey

Ready to achieve clearer skin and better quality of life with expert psoriasis care? Our specialists provide comprehensive, compassionate treatment for lasting results. Join 1309+ patients who trust DermaVue for physician-led dermatology.

WhatsApp TVM Call +91 8330860007

Call WhatsApp